ArticleArchives of medical science : AMS2026
Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has a globally increasing prevalence. Oxidative stress and inflammation, as interdependent processes, play pivotal roles in the pathogenesis of MASLD. Moreover, heritability has a significant impact on MASLD. Hence, to fully understand the nature of complex and multifactorial diseases such as MASLD, it is important to consider the role of genetic and epigenetic factors as essential aspects of a broader context that includes clinical and environmental influences and their interactions when multiple metabolic pathways are involved. While traditional biomarkers may be insufficient in the early stages of this process, new-generation biomarkers and multi-omic approaches hold the potential to contribute to the improvement of disease diagnosis and prognosis. This review article aims to systematically examine oxidative stress and inflammation biomarkers, as well as genetic and epigenetic factors in MASLD, highlighting current diagnostic advances and future perspectives in the field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.